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DrOBJECTIVES This study sought to describe the development of a multicenter, transcatheter aortic valve replacement
program and regional systems of care intended to optimize coordinated, efﬁcient, and appropriate delivery of this new
therapy.
BACKGROUND Transcatheter aortic valve replacement (TAVR) has become an accepted treatment option for patients
with severe aortic stenosis who are at high surgical risk. Regional systems of care have led to improvements in outcomes
for patients undergoing intervention for myocardial infarction, cardiac arrest, and stroke. We implemented a regional
system of care for patients undergoing TAVR in British Columbia, Canada.
METHODS We describe a prospective observational cohort of 583 patients who underwent TAVR in British Columbia
between 2012 and 2014. Regionalization of TAVR care in British Columbia refers to a centrally coordinated, funded, and
evaluated program led by a medical director and a multidisciplinary advisory group that oversees planning, access to care,
and quality of outcomes at the 4 provincial sites. Risk-stratiﬁed case selection for transfemoral TAVR is performed by
heart teams at each site on the basis of consensus provincial indications. Referrals for lower volume and more compli-
cated TAVR, including nontransfemoral access and valve-in-valve procedures, are concentrated at a single site. In-
hospital and 30-day outcomes are reported.
RESULTS The median age was 83 years (interquartile range [IQR]: 78 to 87 years) and median STS score was 6% (IQR:
4% to 8%). Transfemoral access was performed in 499 (85.6%) cases and nontransfemoral in 84 (14.4%). Transcatheter
valve-in-valve procedures in for failed bioprosthetic valves were performed in 43 patients (7.4%). A balloon-expandable
valve was inserted in 386 (66.2%) and a self-expanding valve in 189 (32.4%). All-cause 30-day mortality was 3.5%.
All-cause in-hospital mortality and disabling stroke occurred in 3.1% and 1.9%, respectively. Median length of stay was
3 days (IQR: 3 to 6 days), with 92.8% of patients discharged directly home.
CONCLUSIONS This experience demonstrates the potential beneﬁts of a regional system of care for TAVR. Excellent
outcomes were demonstrated: most patients had short in-hospital stays and were discharged directly home. (J Am Coll
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AB BR E V I A T I O N S
AND ACRONYM S
IQR = interquartile range
TAVR = transcatheter aortic
valve replacement
TF = transfemoral
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1945T ranscatheter aortic valve replacement(TAVR) is a transformative therapy for pa-tients with severe symptomatic aortic steno-
sis who are at high surgical risk (1,2). The procedure
has evolved from a novel technology to a mainstream
treatment modality over the past decade. TAVR re-
quires signiﬁcant expertise and a multidisciplinary
heart team to optimize patient screening, compre-
hensive evaluation, and case selection to individu-
alize procedural planning and risk-stratiﬁed patient
pathways (1). There are varying degrees of complexity
of TAVR patients regarding vascular access ap-
proaches, implantation anatomy, valve selection,SEE PAGE 1952and individual risk proﬁle that may necessitate infre-
quently practiced and specialized skills such as
nontransfemoral-based procedures. The best results
may be achieved through the regional coordination
of these complex patients (3). Regional systems of
care have been shown to improve outcomes in other
cardiovascular conditions such as myocardial infarc-
tion (4), stroke, and cardiac arrest (5). There is limited
reported evidence on the role of a regional approach
to patients requiring TAVR. Ensuring optimized pa-
tient outcomes with minimal complications and
streamlined post-procedure care to reduce hospital
length of stay in TAVR patients will become increas-
ingly important as the procedure is performed more
widely in lower-risk populations. This report aims to
describe the short-term clinical outcomes, including
hospital length of stay and discharge location, as
key performance indicators as a part of a TAVR
regional system of care.
METHODS
IMPLEMENTATION OF A REGIONAL SYSTEM OF
CARE. The British Columbia Transcatheter Heart
Valve (THV) program was established in 2011 by Car-
diac Services BC, an agency of the publicly funded
British Columbia Provincial Health Services Authority
responsible for the planning, coordinating, moni-
toring, evaluating, and funding of cardiac services
across the province, in collaboration with senior ad-
ministrators and physicians. The Provincial Advisory
Panel on Cardiac Health, whose membership includes
cardiologists, cardiac surgeons, referring physicians,served as a consultant for Edwards Lifesciences. Dr. Webb has served as
Medical. All other authors have reported that they have no relationships rel
Manuscript received July 2, 2015; revised manuscript received September 9an ethicist, and other clinical and adminis-
trative stakeholders, recommended the
planning of a single provincial program at
multiple sites. The intent was to leverage
the pioneering work and the expertise gained
at St. Paul’s Hospital, Vancouver (6,7),
to accelerate the implementation of new sites
while maintaining excellent outcomes and improving
patient access. The objectives of establishing a
regional system of care were to guide and monitor
indications in a rapidly changing innovation land-
scape, provide case selection and procedural and
program development mentorship, optimize avail-
able health resources, and support excellent out-
comes from the inception of the new sites. The
template of multidisciplinary collaboration and mul-
timodality assessment established at St. Paul’s Hos-
pital since the earliest procedures performed in 2005
was used to develop a site readiness plan and
mentorship program at 3 additional cardiac centers,
which began in July 2011, March 2012, and July 2012.
The British Columbia TAVR program is led by a
medical director in collaboration with an advisory
group that meets biannually and is comprised of
cardiologists, surgeons, and administrative repre-
sentatives from all centers and referring physicians
from non-TAVR centers. The centers are committed
to program self-regulation and quality improvement.
To this end, the British Columbia TAVR program
mandates the reporting of all procedures, including
data related to eligibility assessment and 30-day and
12-month clinical, echocardiographic, and quality-
of-life follow-up. Data is collected in the BC TAVR
Registry. The Valve Academic Research Consortium
(VARC-2) guidelines are used for endpoint adjudi-
cation. Registry data is further linked to British
Columbia Vital Statistics to report mortality, and
hospital readmissions are veriﬁed with linkage to the
Canadian Institute of Health information Discharge
Abstract Database. A quality report with provincial
and site-speciﬁc structure, process, and outcome
quality indicators is shared yearly with clinical
and administration stakeholders and regional safety
committees for quality assurance purposes. An
annual provincial heart team evaluation meeting in-
clusive of implanting physicians, cardiac imaging,
anesthesiology, critical care, referring cardiologists,
nurse coordinators, and administrators is held toa consultant for Edwards Lifesciences and St. Jude
evant to the contents of this paper to disclose.
, 2015, accepted September 10, 2015.
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1946discuss peer review of quality, case-based learning
and opportunities for quality improvement. Program
funding is contingent on participation in the provin-
cial program; the funding model is on the basis of the
costs of patient care and the device and is reviewed at
regular intervals. Budget allocation reﬂects the
evolving referral patterns, wait list volume, and site
capacity.
Multimodality assessment and eligibility decisions
are conducted in each center by a multidisciplinary
team. In addition to standard diagnostic and medical
consultations required for TAVR, the regional pro-
gram mandates the assessment of functional status,
frailty, and quality of life to help determine patients’
likelihood to derive signiﬁcant beneﬁt for at least
2 years and to measure patient-reported outcomes.
The multidisciplinary team’s recommendation is
documented. For the ﬁrst 6 months following the
opening of the 3 new centers, the medical director
provided input on case selection and was available to
support the implanting team’s learning curve. Simi-
larly, a nurse leader supported the implementation of
the readiness plan and the development of a clinical
pathway.
A transfemoral (TF) approach is the default strat-
egy for all patients; all centers perform TF TAVR and
select their preferred device system. As a starting
point, the British Columbia TAVR program mandated
that patients not suited for TF access are referred to a
central THV site with signiﬁcant accumulated exper-
tise with alternate access procedures (7). Other more
low-volume and complex THV procedures, such as
transcatheter valve-in-valve implantation for failed
surgical bioprosthetic valve (8), or transcatheter
mitral, pulmonary, or tricuspid procedures also result
in referral to a single specialized site. Patient access is
facilitated by nurse program coordinators; the role is
funded by the British Columbia TAVR program with
deliverables focused on standardized referral man-
agement and assessment, wait list management and
triage coordination, follow-up, and data collection.
Medical leaders at each site further facilitate provin-
cial collaboration to promote equitable patient access.
The aim of the present report is to describe the
short-term clinical and procedural characteristics and
outcomes of patients treated with TAVR in BC, using a
range of TAVR device types and access routes, as part
of a comprehensive regional collaborative system
implemented to optimize access to care and support
excellent outcomes in rapidly evolving and innova-
tive treatment options.
DEFINITIONS AND ENDPOINTS. The primary study
endpoint was all-cause 30-day mortality. Secondaryoutcome measures were in-hospital major adverse
cardiac events including all-cause mortality, cere-
brovascular events, myocardial infarction, bleeding
complications, vascular or access-related complica-
tions, and acute kidney injury. Hospital length of
stay and discharge location were also recorded for
patients discharged alive. Serious adverse events
were site-reported and checked for accuracy. All
events were coded according to the standardized
endpoint deﬁnitions proposed by the VARC-2 guide-
lines (9).
STATISTICS. Descriptive summaries are reported for
all TAVR cases, as well as separately by access site. No
statistical comparisons were carried out between TF
and non-TF groups, as the choice of access was
determined by patient indications. Baseline charac-
teristics, procedural details, and clinical outcomes are
reported as counts and percentages for categorical
variables and median and interquartile range (IQR)
for continuous variables. Outcomes for TF cases were
compared by valve types (balloon expandable [Sapien
XT and Sapien 3, Edwards Lifesciences, Irvine, Cali-
fornia] and self-expanding [CoreValve, Medtronic,
Minneapolis, Minnesota]); the chi-square test was
used to compare the proportion of new permanent
pacemakers, and Wilcoxon rank sum test to compare
the hospital length of stay. All analyses were carried
out using SAS software version 9.4 (SAS Institute,
Cary, North Carolina).
RESULTS
A total of 583 patients underwent consecutive TAVR
in BC at 4 sites between 2012 and 2014 for native
aortic valve stenosis (92.6%) and failed aortic bio-
prostheses (7.4%). Baseline characteristics are
described in Table 1. The median age was 83 years
(IQR: 78 to 87 years) and 41% of patients were female.
Patients were highly symptomatic, with 82.3% in New
York Heart Association functional class III or IV.
Patients had severe aortic stenosis with a median
aortic valve area of 0.7 cm2 (IQR: 0.6 to 0.8 cm2) and a
transvalvular gradient of 41 mm Hg (IQR: 31 to 52
mm Hg). Only 7% of patients underwent aortic val-
vuloplasty before TAVR.
Procedural details are highlighted in Table 2. TF
access was performed in 499 (85.6%) cases and non-
TF in 84 (14.4%). Transcatheter valve-in-valve pro-
cedures in patients with failed bioprosthetic valves
were performed in 43 (7.4%). A hybrid operating
theater was utilized in 472 (81.0%) cases, with 102
(17.5%) cases performed under local anesthetic and/or
conscious sedation. A balloon-expandable valve was
TABLE 2 Procedural Details
All
(n ¼ 583)
Transfemoral
(n ¼ 499)
Nontransfemoral
(n ¼ 84)
Time from treatment decision to
procedure, days
37 (16–70) 35 (16–65) 57 (29–99)
Procedure location
Catheterization laboratory 111 (19.0) 111 (22.2) 0
Hybrid operating room 472 (81.0) 388 (77.8) 84 (100)
Awake/conscious sedation 102 (17.5) 102 (20.4) 0
Access site
Direct aortic 6 (1.0) NA 6 (7.1)
Transapical 78 (13.4) NA 78 (92.9)
Transfemoral 499 (85.6) 499 (100) NA
Conversion to open heart surgery 7 (1.2) 3 (0.6) 4 (4.8)
Procedure aborted 8 (1.4) 6 (1.2) 2 (2.4)
Valve implanted 575 (98.6) 493 (98.8) 82 (97.6)
CoreValve 163 (28.3) 161 (32.7) 2 (2.4)
Jenavalve 8 (1.4) 0 8 (9.8)
Lotus 1 (0.2) 1 (0.2) 0
Portico 17 (3.0) 8 (1.6) 9 (11.0)
Sapien 3 50 (8.7) 43 (8.7) 7 (8.5)
Sapien XT 336 (58.4) 280 (56.8) 56 (68.3)
Contrast volume, ml 135 (95–171) 140 (101–175) 94 (55–126)
Fluoroscopy time, min 14 (9–20) 15 (10–21) 6 (5–10)
Values are median (interquartile range) or n (%).
TABLE 1 Baseline Characteristics
All
(n ¼ 583)
Transfemoral
(n ¼ 499)
Nontransfemoral
(n ¼ 84)
Age, yrs 83 (78–87) 84 (79–88) 81 (74–84)
Female 237 (40.7) 188 (37.7) 49 (59.0)
STS PROM, % 6 (4–8) 6 (4–8) 7 (4–10)
Valve area, cm2 0.7 (0.6–0.8) 0.7 (0.6–0.8) 0.7 (0.6–0.8)
Mean gradient, mm Hg 41 (31–52) 41 (31–52) 38 (31–52)
Pacemaker 73 (16.3) 60 (16.0) 13 (17.8)
Prior angioplasty 156 (26.8) 132 (26.5) 24 (28.6)
Prior coronary bypass 138 (23.7) 114 (22.8) 24 (28.6)
Prior AVR 43 (7.4) 34 (6.8) 9 (10.7)
Bridging valvuloplasty 43 (7.4) 32 (6.4) 11 (13.1)
Severe COPD 72 (12.3) 61 (12.2) 11 (13.1)
Dialysis 21 (3.6) 18 (3.6) 3 (3.6)
Severe CKD 62 (10.7) 51 (10.3) 11 (13.1)
Porcelain aorta 47 (8.1) 28 (5.6) 19 (22.6)
NYHA functional class III/IV 480 (82.3) 404 (81.0) 76 (90.5)
LVEF #30% 26 (4.5) 24 (4.9) 2 (2.4)
Values are median (interquartile range) or n (%).
AVR ¼ aortic valve replacement; CKD ¼ chronic kidney disease; COPD ¼ chronic obstruction
pulmonary disease; LVEF¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association;
STS PROM ¼ Society of Thoracic Surgeons predicted risk of mortality.
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1947inserted in 386 (67.1%) and a self-expanding valve in
189 (32.9%). The Sapien XT was implanted in 58.4%,
CoreValve in 28.3%, Sapien 3 in 8.7%, Portico (St.
Jude Medical, St. Paul, Minnesota) in 3.0%, Jenavalve
(Jenavalve, Irvine, California) in 1.4%, and Lotus
valve (Boston Scientiﬁc, Marlborough, Massachu-
setts) in 0.2%. More than 1 transcatheter valve was
required in 2.1% of patients. Eight (1.4%) patients did
not receive any TAVR valve, and 7 (1.2%) had con-
version to open surgical valve replacement during the
index procedure.
The 30-day all-cause mortality was 3.5%. In-
hospital patient outcomes are presented in Table 3.
All-cause in-hospital mortality occurred in 3.1%.
Disabling stroke occurred in 1.9% and myocardial
infarction in 0.9%. Major vascular complications were
reported in 2.2% of patients, with 8.1% experiencing a
major bleeding complication. Analysis of patients
according to access site revealed lower mortality in
TF cases (2.6%) compared with non-TF cases (6.0%).
Similarly disabling stroke (1.6% vs. 3.6%) and major
bleeding (6.8% vs. 15.5%) were lower in TF implants.
Moderate paravalvular regurgitation was seen in
4.9% of patients and severe paravalvular regurgita-
tion in 0.2% at the time of 30-day echocardiography.
Permanent pacemaker implantation was required in
9.1% of patients. Median length of stay for all patients
was 3 days (IQR: 3 to 6 days), with 92.8% of patients
discharged directly home (Tables 4 and 5).
Clinical outcomes were excellent for patients
treated with the Sapien and CoreValve platforms.
Fewer new pacemakers were required (6.2% vs.
18.2%; p < 0.001) and length of stay was shorter
(median 3 days [IQR: 2 to 4 days] vs. 5 days [IQR: 3 to
7.6 days]; p < 0.001) following balloon-expandable
compared with CoreValve TF procedures.
DISCUSSION
The centrally coordinated program infrastructure and
health service planning, mentorship and local lead-
ership, and evaluation framework are unique features
of a regional approach. This study is the ﬁrst multi-
center evaluation of the effect of a regional system of
care on patients undergoing TAVR, encompassing
eligibility assessment, TAVR risk stratiﬁcation, and
utilization of all available TAVR devices. The main
ﬁndings include excellent short-term outcomes
combined with very short hospital stays and over
90% of patients discharged directly home.
Differences in patient characteristics and rapidly
changing TAVR technologies make comparing out-
comes between TAVR registries difﬁcult (Figure 1).
The overall 30-day mortality of 3.5% in high-riskBritish Columbia patients undergoing TAVR as part
of a regional system of care, however, compares
favorably with recent international registry outcomes
(Tables 4 and 5). The U.S. Transcatheter Valve Ther-
apy National Registry of patients undergoing TAVR
TABLE 3 Clinical Outcomes: In-Hospital
All
(n ¼ 583)
Transfemoral
(n ¼ 499)
Nontransfemoral
(n ¼ 84)
All-cause mortality 18 (3.1) 13 (2.6) 5 (6.0)
Death and/or disabling stroke 27 (4.6) 19 (3.8) 8 (9.5)
Any stroke 17 (2.9) 13 (2.6) 4 (4.8)
Disabling stroke 11 (1.9) 8 (1.6) 3 (3.6)
Myocardial infarction 5 (0.9) 5 (1.0) 0
New atrial ﬁbrillation 10 (1.7) 3 (0.6) 7 (8.3)
Acute kidney injury
No 566 (97.1) 486 (97.4) 80 (95.2)
Stage 1 9 (1.5) 6 (1.2) 3 (3.6)
Stage 2 3 (0.5) 3 (0.6) 0
Stage 3 1 (0.2) 1 (0.2) 0
New dialysis 4 (0.7) 3 (0.6) 1 (1.2)
Blood transfusion needed 74 (12.7) 56 (11.3) 18 (21.4)
Blood transfusion, U 2 (1–3) 2 (1–3) 2 (1–4)
Major vascular complication 13 (2.2) 11 (2.2) 2 (2.4)
Minor vascular complication 15 (2.6) 15 (3.0) 0
Life threatening/major bleed 47 (8.1) 34 (6.8) 13 (15.5)
Cardiac arrest 11 (1.9) 6 (1.2) 5 (6.0)
Multiple valves required 12 (2.1) 11 (2.2) 1 (1.2)
New permanent pacemaker 53 (9.1) 51 (10.2) 2 (2.4)
Aortic regurgitation*
None 289 (55.1) 243 (53.9) 46 (62.2)
Mild 211 (40.2) 183 (40.6) 28 (37.8)
Moderate 25 (4.8) 25 (5.5) 0 (0)
Severe 0 (0) 0 (0) 0 (0)
Discharged home* 538 (92.8) 469 (94.2) 69 (84.1)
Hospital stay, days* 3 (3–6) 3 (3–5) 7 (5–11)
Values are n (%) or median (interquartile range). *For cases discharged alive.
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1948with the Edwards Sapien device between 2011 and
2013 indicated a mortality rate of 7.6% (10). The
FRANCE 2 Registry, which like the British Columbia
registry included implantation of balloon-expandable
and self-expanding valves, reported outcomes of
3,195 patients treated in 34 French centers between
2010 and 2011. The 30-day mortality rate was 9.7%
(11). The SOURCE XT (Sapien Aortic Bioprosthesis
European Outcome) Registry, an industry-sponsoredTABLE 4 British Columbia Transfemoral TAVR Outcomes Compared W
BC THV
Registry
TVT
High Risk (10)
TVT
Inoperable (10
N 499 1,687 1,139
Hospital stay, days 3 (3–5) 5 (4–9) 5 (4–9)
Discharge home 94% 67% 70%
30-day mortality 3.0% 4.6% 6.7%
30-day disabling stroke 1.4%‡ 3.2% 1.6%
Values are N, median (range), mean  SD, or %. *Length of stay not stratiﬁed accordin
BC ¼ British Columbia; GARY ¼ German Aortic Valve Registry; TAVI ¼ transcatheter apost-approval European study, reported a 30-day
mortality of 6.3% (12). The Swiss TAVI (Trans-
catheter Aortic Valve Implantation) registry of 697
patients undergoing TAVR between 2011 and 2013
indicated a 30-day mortality of 4.8% (13). The GARY
(German Aortic Valve Registry) reported results in
3,866 patients undergoing TAVR in 2011 (14). Two-
thirds underwent the procedure by a TF approach,
with an in-hospital mortality of 5.1% and a very low
rate of vascular complications, suggesting appro-
priate case selection and highlighting the potential
advantages of a fully percutaneous technique for TF
TAVR. The remaining one-third of procedures were
performed by a transapical approach, with a mortality
of 7.7%.
Our study also indicated higher mortality associ-
ated with the non-TF approach compared with the TF
approach, which is consistent with a higher-risk
cohort with higher rates of peripheral and coronary
arterial disease. Other international reports have also
highlighted increased mortality in patients utilizing
the non-TF approach. The FRANCE 2 registry (TF
8.5% vs. transapical 13.9%; p < 0.001) (11), the U.K.
TAVI registry (TF 5.5% vs. other routes 10.7%; p ¼
0.006) (15), and the recently reported multicenter
trial of the Edwards Sapien 3 valve (TF 2.1% vs. non-
TF 11.1%) (16). The British Columbia registry 30-day
mortality of 6.3% in non-TF access is lower than
other international reports of non-TF–access TAVR
(Table 5). As part of the regional system of TAVR in
British Columbia, all patients requiring non-TF access
are referred to 1 large-volume center with signiﬁcant
expertise in dealing with this high-risk cohort of
TAVR patients (7). Although it is difﬁcult to compare
results across studies, the increasing use of lower-
proﬁle TAVR devices will continue to drive a
decrease in the rate of non-TF access. This trend will
further bolster the potential beneﬁts of a regional
system of care to TAVR by concentrating higher-risk
and lower-volume TAVR procedures at select cen-
ters. Alternatively, the demonstrated improvement inith Other Registries
) FRANCE2 (11) GARY (14) UK TAVI (15) Swiss TAVI (13)
2,361 2,695 599 559
10.5  8.0 NA 8 (6–13)* 10.7  6.0
NA NA NA 29%
8.5% 5.1%† 5.5% 3.6%
3.7% 1.7%† 4.0% 2.2%
g to access. †In-hospital mortality and stroke. ‡In-hospital stroke.
ortic valve implantation; THV ¼ transcatheter heart valve.
TABLE 5 BC Nontransfemoral TAVR Outcomes Compared With Other Registries
BC THV
Registry
TVT
High Risk (10)
TVT
Inoperable (10) FRANCE 2 (11) GARY (13) UK TAVI (15) Swiss TAVI (13)
N 84 1,147 1,139 567 1,181 599 138
Hospital stay, days 7 (5–11) 8 (6–12) 8 (6–11) 13.3  8.0 NA 8 (6–13)* 10.7  6.0
Discharge home 84% 55% 57% NA NA NA 29%
30-day mortality 6.3% 10.8% 12.6% 13.9% 7.7%† 10.7% 9.5%
30-day disabling stroke 3.6%‡ 2.2% 5.9% 2.1% 2.3%† 4.1% 3.7%
Values are N, median (range), mean  SD, or %. *Length of stay not stratiﬁed according to access. †In-hospital mortality and stroke. ‡In-hospital stroke.
Abbreviations as in Table 4.
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1949outcomes over time and increasing standardization of
previously unproven therapies argues for continual
reassessment of which therapies require centralized
expertise, and which do not.
Aortic stenosis is the most common severe valvular
heart disease in developed countries, and its effect on
public health and health care resources is expected to
increase due to aging Western populations (17). There
is a growing focus on regionalized medical care as
a strategy to promote equitable patient access, coor-
dinate triage management, and optimize outcomes,
while managing cost and limited resources (18).
Regional systems of care have been recommended
to maximize patient access to expert-level care in
common cardiovascular conditions such as acute
myocardial infarction (19) and cardiac arrest (20). The
relationship between hospital volume and outcomes
is complex and multifactorial but may also be as-
sociated with improved outcomes in TAVR (21).
Although systems of care for cardiac arrest, acuteFIGURE 1 30-Day Mortality in International High-Risk Transcathete
BC ¼ British Columbia; GARY ¼ German Aortic Valve Registry; TAVI ¼ tmyocardial infarction, and trauma are designed to
foster timely access to time-sensitive conditions,
much may be gained from a similar approach to co-
ordination of care for TAVR. A regional system of care
for TAVR patients can provide ongoing standardized
and coordinated education for patients, providers,
and the community; facilitate dissemination of new
technology and procedures; and maximize the
expertise of specialized services like cardiac imaging
and nursing. A TAVR system of care may serve as
a foundation for cost-effective care through self-
regulation and cardiovascular accountable care orga-
nizations. As evidence emerges that indications for
TAVR may expand and as new transcatheter therapies
become available, a regional system of care can
facilitate the development of consensus recommen-
dations to support health service planning. Regional
systems of care for TAVR should be designed to
standardize and streamline the referral process,
patient assessment and pre-procedural planning,r Aortic Valve Replacement Registries
ranscatheter aortic valve implantation; THV ¼ transcatheter heart valve.
PERSPECTIVES
WHAT IS KNOWN? TAVR is increasingly performed
for elderly patients with symptomatic aortic stenosis.
Implementation of regional systems of care has pro-
vided improved outcomes for a number of complex
cardiac conditions. Whether such systems will also
improve TAVR outcomes is less clear.
WHAT IS NEW? A regional system of TAVR care
was developed and implemented in British
Columbia, Canada, at 4 sites in the province. Non-TF
access and more complicated TAVR procedures were
referred to a single site. All-cause 30-day mortality
was 3.5%, with a short median in-hospital stay of
3 days.
WHAT IS NEXT? Development of coordinated
regional systems of care for TAVR patients may
further improve outcomes.
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1950consensus treatment decisions, appropriate access
route and device selection, and post-procedural care.
Our reported short hospital stays with over 90% of
patients being discharged home is indicative of the
health service beneﬁts of a regional approach to TAVR
care. Although these metrics are infrequently re-
ported in international registries, these measures will
become increasingly important in real word practice
as TAVR expands into lower-risk populations, where
quality of life, program efﬁciencies, and costs will be
important determinants of expanding programs.
STUDY LIMITATIONS. Data completeness in this
province-wide registry was good. The data, including
patients, procedural characteristics, and in-hospital
outcomes, are reported by each site. Core laboratory
analysis was not performed. Although internal con-
sistency and range checks were conducted, and sites
were contacted to clarify missing and unexpected
values, the data were not subject to independent
external validation. Patient wait times are an impor-
tant performance indicator to the effectiveness of
systems of care delivery. The British Columbia regis-
try reports on waiting list times, but does not include
time from referral to initial cardiac consultation,
which, although not considered part of the “surgical
waiting list period,” can be considered part of the
delay from recognition of symptomatic aortic stenosis
until procedure. Additionally, given the signiﬁcant
change in TAVR devices and procedures over time,
we felt that it was less relevant to perform a before
and after analysis of the 1 original site expanding to 4
sites as part of the British Columbia regional system
of care.
The development of a regional system of TAVR
care in BC is also fundamentally linked to the
universal health care system throughout Canada.
Whether similar “spoke and hub” systems can be
implemented in other countries, with different health
systems, remains to be seen. Furthermore, although
the British Columbia TAVR data highlights favorable
short-term outcomes, important differences in pa-
tient baseline characteristics and the increasing
use of later-generation devices throughout BritishColumbia makes comparison of our results to other
registries difﬁcult and was not the aim of this
report. In this initial report of the British Columbia
TAVR registry, we have also avoided risk-adjusted
outcomes due to sample size, which will clearly
become an important component of future data
analyses.
CONCLUSIONS
The excellent short-term clinical outcomes, in
conjunction with most patients having short in-
hospital stays and being discharged directly home,
demonstrates the potential beneﬁts of a regional
system of care for TAVR.
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